Evidence map›Paper›PMID 40097705›Full record

ReviewArchives of microbiology2025

Biosynthesis and yield improvement strategies of fengycin.

Junfeng Sun, Xiaohua Qi, Chunmei Du

Abstract readReview
PubMed Publisher
In one paragraph

Review in Archives of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Junfeng Sun *Engineering Research Center of Agricultural Microbiology Technology, Ministry of Education & Heilongjiang Provincial Key Laboratory of Plant Genetic Engineering and Biological Fermentation Engineering for Cold Region & Key Laboratory of Microbiology, College of Heilongjiang Province & School of Life Sciences, Heilongjiang University, Harbin, 150080, China.
Xiaohua Qi *Engineering Research Center of Agricultural Microbiology Technology, Ministry of Education & Heilongjiang Provincial Key Laboratory of Plant Genetic Engineering and Biological Fermentation Engineering for Cold Region & Key Laboratory of Microbiology, College of Heilongjiang Province & School of Life Sciences, Heilongjiang University, Harbin, 150080, China.
Chunmei DuEngineering Research Center of Agricultural Microbiology Technology, Ministry of Education & Heilongjiang Provincial Key Laboratory of Plant Genetic Engineering and Biological Fermentation Engineering for Cold Region & Key Laboratory of Microbiology, College of Heilongjiang Province & School of Life Sciences, Heilongjiang University, Harbin, 150080, China. 2002092@hlju.edu.cn.

Funding

National Natural Science Foundation of China 32172468
6 · The paper itself

Abstract

Fengycin is a cyclic lipopeptide antibiotic predominantly synthesized by Bacillus species. It exhibits remarkable antifungal, antitumor, and antiadhesion activities. It also possesses advantageous properties such as low toxicity, effective antibacterial activity, and biodegradability, making it a promising candidate for applications in biocontrol, medicine, and industry. However, challenges including low yield, complex purification processes, and high production costs currently restrict its large-scale commercialization. To promote the research and development of fengycin and facilitate its practical applications, this review summarizes fengycin's structural characteristics, subclasses, and producing bacteria. Additionally, it delves into the biosynthesis process, known regulatory factors and mechanism, as well as strategies for enhancing yield through strain improvement and fermentation condition optimization. Furthermore, it addresses the limitations and future directions for fengycin research. This review provides a valuable insights and guidance for future researchers aiming to expand fengycin's applications in medical and agricultural fields. This work also establishes a theoretical foundation for realizing its significant commercial potential.

Indexed as

Anti-Bacterial AgentsBacillusLipopeptidesFermentationAnti-Bacterial AgentsfengycinLipopeptidesApplication prospectBiosynthesisFengycinStrategies for increasing productionStructural characteristics

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.